The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma
Biomolecules · 2025
DOI: 10.3390/biom15101436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Yilan He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. Hauptthemen laut MEDLINE: Uveal Neoplasms, Melanoma, Adrenergic alpha-Antagonists, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Because of its high potential for spreading and its limited response to treatment, UM remains a clinical challenge. Previous studies suggest that clinical adrenergic receptor (AR) antagonists might be effective in the treatment of UM. This study reports the antitumor activity of α-blocker in UM spheroids generated from α1A- and α2A-AR-positive UM cell lines. These cell lines were derived from primary tumors or hepatic metastases and differed in their genetic risk status for metastasis. Drug screening with UM spheroids revealed that prazosin and doxazosin dose-dependently reduced viability, whereas terazosin, alfuzosin, silodosin, tamsulosin, and phenoxybenzamine were found to be inefficient. Prazosin induced apoptosis, resulting in the disintegration of UM spheroid morphology and growth inhibition. Additionally, prazosin prevented UM spheroid cell outgrowth and long-term survival, indicating potential for tumor control. Like the selective α1A-AR antagonist RS17053, prazosin inhibited the formation and growth of UM spheroids stimulated by the α1-agonist phenylephrine. This suggests a tumor-preventive effect through the blockade of α1A-AR. The present study highlights the responses of UM spheroids to α-AR antagonists and demonstrates that prazosin, doxazosin, or RS17053 may be a treatment option for preventing UM tumor recurrence or metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
- Nanchong Hospital, Beijing Anzhen Hospital, Capital Medical University, Renmin South Road No. 97, Nanchong 637000, China.
- Ophthalmology Center, Zhoushan Hospital, Wenzhou Medical University, Dingshen Road No. 739, Zhoushan 316021, China.
- Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
ORCID-Profile: Yilan He, Tienush Rassaf, Nikolaos E Bechrakis
Zitieren
APA
He, Y., Liu, H., Hendgen-Cotta, U., Rassaf, T., Bechrakis, N. E., & Berchner-Pfannschmidt, U. (2025). The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. Biomolecules. https://doi.org/10.3390/biom15101436
Vancouver
He Y, Liu H, Hendgen-Cotta U, Rassaf T, Bechrakis NE, Berchner-Pfannschmidt U. The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. Biomolecules. 2025. doi:10.3390/biom15101436
BibTeX
@article{He2025,
author = {He, Yilan and Liu, Hongtao and Hendgen-Cotta, Ulrike and Rassaf, Tienush and Bechrakis, Nikolaos E and Berchner-Pfannschmidt, Utta},
title = {The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15101436}
}
EUVIMED